BI 1823911 trial in advanced KRAS-mutant cancer stays active but no longer recruiting
ClinicalTrials.gov shows a Phase 1 Boehringer Ingelheim study of BI 1823911 in advanced KRAS-mutant cancer as ACTIVE_NOT_RECRUITING, with monotherapy and combination therapy arms and no posted results yet.
A ClinicalTrials.gov registry observation published 2026-11-10T00:00:00+00:00 shows a Phase 1 study of BI 1823911 in people with different types of advanced cancer with KRAS mutation. The study is ACTIVE_NOT_RECRUITING, so it is still underway but no longer taking new participants, and there are no posted results yet.
For patients and families following cancer research, that status matters because it marks a live test of a treatment approach without telling us whether it has worked. The record points to two paths being studied: BI 1823911 by itself and BI 1823911 combined with other medicines.
"This record describes a study and its registry status; study outcomes require posted results."
What the study is testing
The study title says it is testing different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation. The sponsor listed is Boehringer Ingelheim, and the allocation is NON_RANDOMIZED, meaning participants are not assigned by chance to different groups.
Two experimental arms are named in the registry entry: Monotherapy Arm and Combination Therapy Arm. The interventions listed are BI 1823911 in both arms, BI 1701963 in the Combination Therapy Arm, and Midazolam in the Monotherapy Arm.
"Allocation": "NON_RANDOMIZED"
How progress will be judged
The primary outcomes focus first on dose finding. During the up to 28 days dose-escalation period, the study is tracking dose limiting toxicities, often called DLTs, which are side effects severe enough to stop further dose increases.
Later parts of the study look at objective response, defined in the registry as best overall response of confirmed complete response or confirmed partial response. That measure is planned for dose confirmation and expansion, with a time frame of up to 39 months and response judged using RECIST version 1.1, a standard cancer imaging framework.
"Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination"
Why this update is worth watching
The estimated primary completion date is 2026-11-29, which gives this registry entry a near-term milestone to watch, but it is still only an estimate. Until results are posted, the safest reading is simply that the study remains active and the research team is continuing to evaluate dose, safety, and response.
For readers tracking the broader cancer research stream, this entry fits the Cancer Breakthroughs special event because it adds another active cancer study centered on a targeted treatment approach. It does not settle whether BI 1823911 will help, but it does show the program moving through a structured Phase 1 process.
"Primary completion date": "2026-11-29"